CASI Pharmaceuticals Inc

ENM

Company Profile

  • Business description

    CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

  • Contact

    No. 81, Jianguo Road
    Room 1701-1702, China Central Office Tower 1
    Huamao Office Building, Chaoyang District
    Beijing100025
    CHN

    T: +86 01065618789

    E: [email protected]

    https://www.casipharmaceuticals.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    233

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,828.7056.700.65%
CAC 407,738.4275.830.99%
DAX 4023,790.11116.820.49%
Dow JONES (US)44,484.4210.52-0.02%
FTSE 1008,774.6910.64-0.12%
HKSE24,221.41149.130.62%
NASDAQ20,393.13190.240.94%
Nikkei 22539,762.48223.85-0.56%
NZX 50 Index12,784.2949.760.39%
S&P 5006,227.4229.410.47%
S&P/ASX 2008,597.7056.600.66%
SSE Composite Index3,454.792.95-0.09%

Market Movers